PDA

View Full Version : TPIV - TapImmune, Inc.



Adriannep
09-29-2015,
About TapImmune, Inc.

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or ‘accelerant’ to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010.

The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens among others.

http://www.tapimmune.com/

alkuqvdgzzqk
09-30-2015,
Nice news today
TapImmune Announces Acquisition of Additional Technology

Company Completes Technology and IP Acquisition From The UBC Pursuant to an Option Agreement
On Wednesday August 5, 2009, 6:00 am EDT

http://finance.yahoo.com/news/TapImm....html?x=0&.v=1

aqaqayi
10-01-2015,
BELLEVUE, WA--(Marketwire - 08/05/09) - TapImmune Inc. (OTC.BB:TPIV - News), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announces the acquisition of three follow-on inventions and IP relating to its key TAP technology from The University of British Columbia.

"These inventions add depth to our pipeline and strengthen the intellectual property position of our TAP technology platform," said Denis Corin, President of TapImmune Inc.

http://finance.yahoo.com/news/TapImm....html?x=0&.v=1

http://www.tapimmune.com/